导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.79% | 1754/4773 |
| 近一周 | -1.60% | 2359/5465 |
| 近一月 | -3.38% | 2447/5421 |
| 近一季 | -6.40% | 2399/5231 |
| 近半年 | -0.87% | 1610/4920 |
| 近一年 | 7.00% | 1526/4394 |
| 近两年 | 65.85% | 1088/2954 |
| 近三年 | 43.53% | 681/2253 |
| 成立以来 | 69.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.80% 2486/4961 |
15.77% 1630/5312 |
- - |
- - |
| 2025 | 26.53% 1624/4813 |
0.38% 1875/3635 |
2.71% 1407/4076 |
21.35% 1812/4524 |
1.13% 1507/4813 |
| 2024 | 17.39% 696/3463 |
1.76% 856/2808 |
-1.99% 1126/3014 |
18.02% 1075/3129 |
-0.27% 1364/3463 |
| 2023 | -6.62% 864/2656 |
5.70% 759/2280 |
-3.83% 921/2385 |
-2.64% 707/2515 |
-5.65% 1440/2655 |
| 2022 | -19.64% 875/2207 |
-14.39% 941/1919 |
6.28% 734/2016 |
-13.45% 907/2113 |
2.06% 1055/2208 |
| 2021 | 1.94% 646/1822 |
-3.20% 779/1255 |
6.56% 737/1330 |
-3.36% 635/1466 |
2.27% 639/1822 |
| 2020 | 43.87% 237/1250 |
-6.47% 487/1028 |
18.04% 355/1067 |
15.35% 220/1164 |
12.96% 407/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证800ETF VS. 长安沪深300非周期A(740101) |